Metabolic profiling of a transgenic Caenorhabditis elegans Alzheimer model by Van Assche, Roel et al.
ORIGINAL ARTICLE
Metabolic profiling of a transgenic Caenorhabditis elegans
Alzheimer model
Roel Van Assche • Liesbet Temmerman •
Daniel A. Dias • Berin Boughton • Kurt Boonen •
Bart P. Braeckman • Liliane Schoofs • Ute Roessner
Received: 24 April 2014 / Accepted: 11 July 2014 / Published online: 30 July 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract Despite decades of research, no early-onset
biomarkers are currently available for Alzheimer’s disease,
a cureless neurodegenerative disease afflicting millions
worldwide. In this study, transgenic Caenorhabditis ele-
gans were used to investigate changes in the metabolome
after induced expression of amyloid-b. GC- and LC–MS-
based platforms determined a total of 157 differential
features. Some of these were identified using in-house
(GC–MS) or public libraries (LC–MS), revealing changes
in allantoin, cystathionine and tyrosine levels. Since C.
elegans is far better suited to metabolomics studies than
most other model systems, the accordance of these findings
with vertebrate literature is promising and argues for fur-
ther use of C. elegans as a model of human pathology in
the study of AD.
Keywords Metabolomics  Metabolic profiling 
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1 Introduction
Alzheimer’s disease (AD) is the most common cause of
dementia, accounting for over 70 % of all cases worldwide
(World Alzheimer’s Report, 2009). In addition, AD causes a
severe social and financial impact on patients and their
environment. The number of patients worldwide with AD is
estimated at a current 24 million, a number that will have
tripled by 2050 (World Health Organization, 2012). AD is a
progressive disease with a long preclinical phase of
10–15 years (Tarawneh and Holtzman 2012), which creates
opportunities for a biomarker detection approach. AD is
characterized by inflammation, neuronal loss, intracellular
aggregation of the protein tau and extracellular plaques of the
peptide amyloid-b. Amyloid-b, generated from the amyloid-
b precursor protein (APP), is mainly processed in an anti-
amyloidogenic manner (Haass et al. 2012). However, in AD
patients, APP is overly processed according to the amyloi-
dogenic pathway, which leads to the release of aggregating
amyloid peptides (Haass et al. 2012). Additionally, the
microtubule stabilizing protein tau becomes hyperphos-
phorylated and forms intracellular neurofibrillary tangles
(Mandelkow and Mandelkow 2012). Since there is no cure
for AD, it is becoming increasingly more important to find
early pathological markers which could easily be measured
by a non-invasive method, prior to the emergence of clinical
symptoms.
Current biomarkers in cerebrospinal fluid (CSF) are the
amount of total tau, phosphorylated tau, amyloid-b (Blen-
now et al. 2012) and the 42/40 ratio of amyloid-b (Wiltfang
et al. 2007). Although CSF removal is an uncomfortable,
invasive procedure, it is often used to diagnose AD. A range
of imaging techniques has been developed over the last
couple of years to improve the diagnosis of AD (Johnson
et al. 2012). Despite the improvement of fluid biomarker
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discovery and imaging techniques, AD is typically diag-
nosed when patients start displaying cognitive impairment.
Recently, researchers have started turning towards meta-
bolomics as a promising method to assist in the search for
early biomarkers of AD (Trushina and Mielke 2013).
Metabolomics uses a range of sensitive and comple-
mentary analytical platforms to study the levels of small
molecules in cells, tissues, bio-fluids and entire organisms,
referred to as the metabolome (Roessner and Bowne 2009).
Because gene expression, protein activity and environment
all exert certain influences on the metabolome, metabolo-
mic readouts closely reflect cellular processes and provide
highly accurate snapshots of an organism’s state. Two
platforms are mainly used: gas or liquid chromatographic
separation hyphenated to mass spectrometry (GC–MS and
LC–MS) and nuclear magnetic resonance (NMR)-based
spectroscopy (Temmerman et al. 2013). Current literature
on metabolomics related to AD is rather limited and a
distinct set of metabolic markers has not yet been discov-
ered (Graham et al. 2013a, b; Kaddurah-Daouk et al. 2011,
2013; Lin et al. 2013; Mapstone et al. 2014; Motsinger-
Reif et al. 2013; Oresˇicˇ et al. 2011; Salek et al. 2010; Sato
et al. 2012; Trushina et al. 2013). This may in part be due
to the underlying heterogeneity of the sample groups. To
improve this issue, the use of a model can be advantageous.
Model organisms are used to investigate the function of
certain factors in a simplified system in comparison to
humans. Many model organisms have been used in the
study of AD (e.g. Saccharomyces cerevisiae (De Vos et al.
2011), Caenorhabditis elegans (Link 2006), Drosophila
melanogaster (Iijima-Ando and Iijima 2010), Mus muscu-
lus (Elder et al. 2010). Here, C. elegans was chosen
because it allows for the most stringent level of experi-
mental control in the study of multicellular organisms. This
addresses the importance of minimizing unwanted varia-
tion, especially necessary when using sensitive techniques
like metabolomics, biomarker discovery and compound
screens. A transgenic, temperature-sensitive strain
expressing amyloid-b in the neurons was selected, enabling
time- and site- controlled expression of the transgene. Such
strains have already proven their value in AD research in
the study of amyloid-b aggregation (Fay et al. 1998), gene
expression (Link 2003), toxicity screening (Dostal and
Link 2010), learning behavior (Dosanjh et al. 2010) and
proteomic changes (Boyd-Kimball et al. 2006). In this
study, a metabolic fingerprint was generated of a well-
established (Boyd-Kimball et al. 2006; Dosanjh et al. 2010;
Dostal and Link 2010; Link 1995, 203) transgenic AD
strain in order to monitor metabolic changes due to
expression of amyloid-b. Both non-targeted GC–MS and
LC–MS analyses were performed, ensuring a broad
detection of the extracted metabolites. LC–MS analysis
was further refined using two different chromatographic
separation methods (reversed phase (RP) and aqueous
normal phase (ANP)). Because C. elegans can be used to
screen a large amount of metabolites in a relatively short
time, these findings will form the basis of future testing of
drug efficiency and the mode-of-action during AD
progression.
2 Materials and methods
2.1 C. elegans culture and sampling
Temperature-sensitive transgenic (CL2355) and control
(PD8120) strains were kindly provided by Professor
Christopher Link (University of Colorado at Boulder,
USA). Strains were cultured at 16 C on standard nema-
tode growth medium (NGM) agar seeded with Escherichia
coli OP50 bacteria (Brenner, 1974). CL2355 (smg-
1(cc546);dvIs50 [pCL45 (Psnb-1::Ab1-42::30 UTR(-
long) ? Pmtl-2::GFP]) drives pan-neuronal expression of
the peptide Ab1–42 under control of the C. elegans syna-
ptobrevin (snb-1) promoter. The expression can be induced
by a temperature upshift from 16 to 23 C (Fig. 1), as a
result of the temperature-sensitive smg-1ts background,
also present in the control strain, in which nonsense-med-
iated mRNA decay (NMD) is disturbed upon temperature
upshift (Link 2003).
Age-synchronized transgenic and control strains were
cultured in liquid medium with E. coli K12 as a food source,
for 34 h at 16 C. Food availability was held constant
(OD600 = 1.68) by adding bacteria twice a day during cul-
turing. After 34 h, both strains were shifted to 23 C,
inducing the expression of Ab1-42 in the AD strain only.
Another 30 h later, worms were collected by pelleting on ice
(Fig. 1). The removal of bacteria and debris was carried out
using a sucrose-flotation (60 % sucrose). After collection,
the worms were washed with S-buffer (Brenner 1974) for 5
times and partitioned into aliquots of maximum 0.3 ml per
tube (Precellys lysing kit, Bertin Technologies). The aliquots
were snap frozen in liquid nitrogen and stored at -80 C.
A total of 14 biologically independent samples for each
condition were used. As negative controls, three samples of
each condition without temperature upshift were produced,
in addition to four supernatant samples. The latter were
used to establish the metabolite baseline of the medium:
features extracted from these negative controls were
omitted from all further sample analyses.
2.2 Extraction
We opted for an extraction using ice-cold 80 % methanol,
as described earlier for C. elegans (Geier et al, 2011). Ice-
cold methanol, containing an external standard (13C6-
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sorbitol (0.5 mg ml-1), 13C5
15N-Valine (0.5 mg ml-1),
2-aminoanthracene (0.25 mg ml-1) and pentafluoroben-
zoic acid (0.25 mg ml-1), was added to the worm pellet
until 80 % methanol was reached. All samples were
homogenized at low temperature (Precellys 24, Bertin
Technologies; 2 9 30 s, 4800 rpm, -20 C) to avoid
potential metabolite degradation. Subsequently, samples
were held on ice for 15 min and were then centrifuged for
15 min at 13,000 rpm. Supernatants were transferred to
new Eppendorf tubes and pellets were re-extracted with
80 % methanol. To avoid protein contamination, all sam-
ples were filtered using a 3 kDa cutoff filter (Amicon Ultra
UFC500308). Both supernatants were combined and re-
divided into 3 aliquots for GC–MS and LC–MS (RP and
ANP coupled to quadrupole time of flight mass spec-
trometry (Q-TOF)) analyses. These aliquots were dried
using a speed-vacuum concentrator and then stored at
-80 C until analysis.
2.3 GC–MS analysis
The dried samples were redissolved in 10 ll of
30 mg ml-1 methoxyamine hydrochloride in pyridine
and derivatised at 37 C for 120 min with mixing at
500 rpm. The samples were then treated for 30 min with
20 ll N,O-bis-(trimethylsilyl)trifluoroacetamide (BSTFA)
and 2.0 ll retention time standard mixture [0.029 %
(v/v) n-dodecane, n-pentadecane, n-nonadecane, n-doco-
sane, n-octacosane, n-dotriacontane, n-hexatriacontane
dissolved in pyridine] with mixing at 500 rpm. Each
derivatised sample was allowed to rest for 60 min prior
to injection.
Samples (1 ll) were injected into a GC–MS system
comprised of a Gerstel 2.5.2 autosampler, a 7890A Agilent
gas chromatograph and a 7000 Agilent triple-quadrupole
MS (Agilent). The MS was adjusted according to the
manufacturer’s recommendations using tris-(perfluorobu-
tyl)-amine (CF43). The GC was performed on a 30 m VF-
5MS column with 0.2 lm film thickness and a 10 m
Integra guard column (J & W, Agilent). The injection
temperature was set at 250 C, the MS transfer line at
280 C, the ion source adjusted to 250 C and the quad-
rupole at 150 C. Helium was used as the carrier gas at a
flow rate of 1.0 ml min-1. For the polar metabolite ana-
lysis, the following temperature program was used; start at
injection 70 C, a hold for 1 min, followed by a 7 C
Fig. 1 Scheme of experimental
setup. Both AD model and
control strains were cultured for
34 h at 16 C. After this period,
a temperature upshift to 23 C
was performed, inducing
amyloid-b42 expression in the
AD strain only. Thirty hours
later, worms were collected and
snap frozen with liquid nitrogen.
An 80 % ice-cold methanol
extraction was performed and
samples were aliquoted for GC–
MS, RP-QTOF or ANP-QTOF.
A After data-analysis, features
that were putatively identified
showed a similar pattern as seen
in previous human AD research.
B Some of our unidentified
features could be linked to LC–
MS AD metabolomics profiling
literature
Transgenic Caenorhabditis elegans Alzheimer model 479
123
min-1 oven temperature ramp to 325 C and a final 6 min
heating at 325 C in which the data was acquired in full-
scan mode. Both chromatograms and mass spectra were
evaluated using AMDIS (NIST, www.chemdata.nist.gov)
and Agilent MassHunter Workstation Software, Quantita-
tive Analysis, Version B.05.00/Build 5.0.291.0 for GCMS.
Mass spectra of eluting compounds were identified using
NIST08 database and the in-house Metabolomics Australia
mass spectral library. All matching mass spectra were
additionally verified by determination of the retention time
and index in comparison to those of standard substances.
Every six samples, a pooled instrument control sample
consisting of 54 standard compounds was run to evaluate
potential retention time shifts and loss in sensitivity (Sup-
plemental Fig. 1). As can be expected for GC, all quality
control runs overlapped clearly and no significant retention
time shift was present. A significant loss in sensitivity was
not observed. It can therefore be taken into account by
normalization strategies (see below). None of the differ-
ential and identified metabolites had multiple TMS deriv-
atives. All data were exported as a comma separated value
file for further data analysis.
2.4 LC–MS analysis
2.4.1 Materials
LC–MS grade formic acid and ammonium acetate were
purchased from Sigma-Aldrich (Sydney, Australia). Deion-
ized water (18.2 MX) was used throughout all experiments.
HPLC grade methanol and acetonitrile (ACN) were pur-
chased from Burdick and Jackson (Ajax, Sydney, Australia).
Reversed phase (RP) chromatography was done using a
Zorbax Eclipse XDB-C18 m 2.1 9 100 mm, 1.8 lm (Agi-
lent, Santa Clara, CA, USA). The Cogent diamond hybrid
2.1 9 100 mm, 4 lm particle size ANP column was pur-
chased from MicroSolv Technology (Brisbane, Australia).
2.4.2 LC–MS system
In this experiment an Agilent 1200 series HPLC was used
(Santa Clara, CA, USA) comprising of a vacuum degasser,
binary pump, thermostated auto sampler and column
compartment. Extraction procedures, solvent gradients,
concentration sample, column conditions and mass spec-
trometer settings were optimized using pooled samples;
reflecting an averaged sample of the overall experiment.
The settings found to be optimal for C. elegans metabolites
were then used for all subsequent runs. For RP chroma-
tography, a 10 min linear gradient of 95:5 water/ACN to
5:95 water/ACN at 0.4 ml min-1 was used while the
column temperature was held at 50 C. Both mobile phases
contained 0.1 % formic acid. For the complementary ANP
procedure, solvents were made with uttermost care and the
system was thoroughly flushed to ensure a proper separa-
tion of the metabolites. The organic mobile phase solvent
(B) was composed of 90 % ACN with 0.1 % (w/v)
ammonium acetate and 0.1 % acetic acid. The aqueous
mobile phase (A) was composed of 100 % deionized water
with 0.1 % (w/v) ammonium acetate and 0.1 % acetic acid
(pH 3.4). The column flow-rate was 0.4 ml min-1 and
column temperature was kept at 50 C. The optimal gra-
dient started at 100 % B then linearly decreased to 40 % B
over 10 min, followed by a 1 min hold at 40 % B. The
column was then re-equilibrated at 100 % B for 6 min20.
For both modes, a washing step was added every run to
control for unwanted carry-over. Every six samples, a
pooled biological control sample was run to evaluate
potential retention time shifts and variations in mass
accuracy (Supplemental Fig. 2). Retention time shifts were
never bigger than 0.1 min and the average deviation of the
mass accuracy always remained lower than 1.78 ppm
(Supplemental Table 1).
The mass spectrometer used was an Agilent 6520 QTOF
MS system (Santa Clara, CA, USA) with a dual spray ESI
source. The conditions for the source were: nebulizer
pressure of 45 psi, gas flow-rate of 10 l min-1, gas tem-
perature 300 C, capillary voltage of 4 kV and skimmer
65 V. Measurements were performed in the extended
dynamic range mode (m/z range of 70–1700 amu), both in
positive and negative ion mode and collecting centroid data.
Data were exported as.mzdata to be further analyzed in
MZmine 2.10 (Pluskal et al. 2010). In addition, to increase
the accuracy of the identification, high resolution (70,000),
more accurate (\3 ppm) MS and MS/MS data of differen-
tial features were obtained by running pooled samples using
a ‘top 10’ method on a Q Exactive Hybrid Quadrupole-
Orbitrap mass spectrometer (Thermo Scientific).
LC–MS data analysis was performed using MZmine
2.10 (Pluskal et al. 2010). After centroid peak detection,
all data points above the noise level were processed as
pairs of m/z and intensity values. Peak lists were created
using the chromatogram builder. The chromatograms
were deconvoluted and isotopic peaks were grouped.
Finally, peak lists were aligned using the random sample
consensus (RANSAC) alignment method (Pluskal et al.
2010). After filtering and gap filling, the data matrix was
exported as a comma separated value file for further
processing. All parameters were optimized for each data
collection mode. LC–MS identification was performed
using public databases (HMDB, KEGG and Metlin).
Based on mass value (Dppm \ 10 ppm) and accurate
mass (Dppm \ 3 ppm) features were matched against
these databases.
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2.5 Data analysis
Statistical analysis was performed using the R package
metabolomics (De Livera et al. 2013) and the MetaboAn-
alyst webserver (Xia et al. 2012). An initial log2 transfor-
mation was applied to obtain a normal distribution. After
this transformation, the dataset was median normalized and
a combination of multivariate and univariate statistical tests
was performed. Principal components analysis (PCA), an
unsupervised explorative data analysis method, was per-
formed to evaluate the overall variance in the obtained
datasets. Similarly, supervised partial-least squares dis-
criminant analysis (PLS-DA) was conducted to better
explore the variance differentiating the two experimental
conditions (AD vs. control). Variable Importance in Pro-
jection (VIP) scores represent which of the features con-
tribute most to the differentiation of the experimental
groups in PLS-DA analysis. Significant differences in
abundance of individual features between conditions were
evaluated using a standard t test. All p values were adjusted
according to the Benjamini & Hochberg principle to take
false discovery rate into account.
3 Results and discussion
There are already a few reports on the metabolome of
human AD cerebrospinal fluid (CSF) (Kaddurah-Daouk
et al. 2011, 2013; Oresˇicˇ et al. 2011; Trushina et al. 2013)
(Graham et al. 2013a), plasma (Trushina et al. 2013) and of
CSF reflecting the pathological progress from mild cogni-
tive impairment to AD (Oresˇicˇ et al. 2011). Despite these
research efforts, working with human samples implies a
high level of inherent variation (age, sex, diet, medical
history, etc.), which may mask relevant results. Therefore,
use of more controllable model organisms can help to
deliver a more delineated fingerprint, which can then be
used for targeted studies in patients. Based on this rea-
soning, metabolic analyses on transgenic AD mice (Fuku-
hara et al. 2013; Graham et al. 2013b; Salek et al. 2010)
revealed a widespread perturbation of metabolism in dif-
ferent tissues and bio fluids. In the same vein, here C.
elegans was used to discover metabolic changes due to AD
by generating a metabolic fingerprint of a transgenic, pan-
neuronal amyloid-b strain.
Caenorhabditis elegans is a suitable model organism to
screen multiple drug compounds efficiently and has the
potential to discover markers for diseases in a cheap, fast
and controlled manner. Metabolomics has proven its value
for C. elegans research (Fuchs et al. 2010; Hughes et al.
2009), although profiling, to our knowledge has not been
performed with transgenic C. elegans AD models. We used
a metabolic approach to evaluate the C. elegans amyloid-b
AD model, relying on a combination of GC–MS and four
LC–MS platforms (ANP-MS and RP-MS, each acquired in
positive and negative ion mode).
3.1 Overall feature detection and sample separation
A clear chromatographic separation was achieved for all
approaches (Fig. 2), resulting in a final total of 157 dif-
ferential features (p value \0.05) (Table 1). Mean nor-
malized abundance and standard deviation of all samples in
all modes were determined (Supplemental Table 2).
Unsupervised multivariate statistics did not always
succeed in separating the experimental groups (Supple-
mental Figs. 3, 4). Principal components analysis (PCA)
generally resulted in a modest separation of the experi-
mental groups. Poor PCA plot separations are also the case
in similar studies (Lin et al. 2013; Trushina et al. 2013), but
these rely on less controllable model systems. This could
possibly be explained by the sample type: as opposed to
human CSF or brain tissue samples, we used whole-mount
extracts for analysis. Therefore, the behavior of some dif-
ferentiating features might yet be diluted or masked. Even
though the central nervous system is the actual site of
interest, it can currently not be distinguished from other
tissues in C. elegans. Nevertheless, partial least squares
discriminant analysis (PLS-DA) in combination with var-
iable importance in projection tables (Supplemental
Figs. 5–11) illustrate that observed differential features
considerably contribute to the separation of the two groups.
Evaluation of volcano plots, showing the significance and
fold-changes of all data points, was also indicative of a
defined set of robustly differential features (Supplemental
Figs. 12–16).
3.2 Differential features as a result of AD pathology
in C. elegans
For the GC approach every peak corresponding to a feature
was manually selected and compared to a library of ref-
erence compounds, resulting in a final list of 76 unique
compounds. Upon differential analysis, only a few known
metabolites were significantly altered in AD conditions as
compared to controls (Table 2). Of all features, 38 % could
not be identified because of a lack of corresponding library
entry (in-house or NIST08) (Supplemental Fig. 17).
LC–MS data were acquired in positive and negative ion
mode, each combined with two separation methods (RP
and ANP) (Fig. 2). As such, an elaborate spectrum of
metabolites could be examined. RP and ANP methodolo-
gies are suitable for differing sub-populations of the me-
tabolome, explaining why only a few features were seen in
both approaches. Features detected in both ANP and RP
delivered similar readouts (Supplemental Fig. 18),
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providing corroborative evidence for the observed results.
LC–MS profiling resulted in a detection of 2,096–11,039
features, depending on the acquisition mode (ANP-MS
negative mode: 2096; ANP-MS positive mode: 4424; RP-
MS negative mode: 5992; RP-MS positive mode: 11039).
It is immediately clear that the RP negative mode dataset
shows the highest amount of differential features (Table 1,
Supplemental Table 3). By looking in further detail to this
mode, many features were observed to co-elute and have
similar fold changes. This may imply that a single
metabolite may be present as a number of adducts which
could lead to deconvolution of several related features.
Therefore, an adduct search using the CAMERA package
was performed on RP negative mode data (Kuhl et al.
2012). Approximately 15 % of the features were identified
as adducts. The most significant differential (p value
\0.01) features are presented in Table 3, remaining dif-
ferential results are shown in supplemental Table 3. In
sum, LC–MS analysis revealed 149 differential features,
mostly detected from reversed phase LC in combination
with negative ion mode.
By comparing the obtained results with research on AD
LC–MS metabolomics literature (Lin et al. 2013; Trushina
Fig. 2 Representative UPLC ESI-base peak chromatograms of C. elegans extracts from different platforms. X-axis: Retention time (from 0 to
14 min), Y axis: Peak intensity (total ion count from 0 to 8.0E6)
Table 1 Total of differential features in different modes
Differential features different modes
Method Ion mode Differential features
LC–MS: RP ? 14
LC–MS: RP - 113
LC–MS: ANP ? 21
LC–MS: ANP - 1
GC–MS ? 8
LC liquid chromatography, RP reversed phase, ANP aqueous normal
phase, GC gas chromatography)
Table 2 Significant GC–MS (p value \0.05) features with mass
identifiers, retention time, p value (*adjusted according to the Ben-
jamini & Hochberg principle), Z-factor, fold change and identity
GC–MS differential features
Mass
identifiers
RT p value* Z-
factor
Fold
change
Identity
188 15.1 0.0253 -1.75 3.33 Unknown
314, 329 15.5 0.0253 -3.28 1.93 Unknown
411 31 0.0253 -6.2 0.56 Unknown
299 16.2 0.0253 -3.51 1.88 Unknown
403, 189 17.2 0.0253 -3.04 0.53 Unknown
264, 279 20.8 0.0253 -3.06 1.83 Allantoin
278, 245 25.3 0.0253 -3.34 0.54 Cystathionine
243, 128 15 0.0481 -3.83 1.58 Unknown
218, 280 21.8 0.0022 -11.09 1.35 Tyrosine
Z-factor provides a useful tool for comparison and evaluation of the
quality of the assay (Zhang 1999)
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et al. 2013), some putative features were found with
matching mass (Dppm \ 50 ppm) and similar fold changes
(Fig. 1; Table 3, Supplemental Table 3). These confirm
that the same reactions might be (de)activated in C. elegans
when comparing to mouse or human. Since most meta-
bolomics experiments conducted to date relied on targeted
methods, it can be assumed that this number is an under-
estimation of the actual correspondence (i.e. when com-
paring to other non-targeted studies). In addition, more
corresponding features can be expected if not only amy-
loid-b1–42, but also the protein tau would be expressed in
the C. elegans model. Amyloid-b1–42 probably only indu-
ces a part of the metabolic changes which occur in AD
(Ittner and Go¨tz 2011), therefore, adding tau might better
reflect the biochemical changes related to AD progression.
3.3 Known metabolic markers of AD
In our C. elegans experiments, several putatively identified
metabolites correspond to metabolites previously associ-
ated with AD pathology (Tables 2, 3). These are of special
interest for further discussion. A higher level of allantoin
was observed in our experiments in C. elegans, matching
observations in human plasma and mice (Fukuhara et al.
2013; Zitnanova´ et al. 2004). Allantoin is produced in a
non-enzymatic oxidation reaction when uric acid is
exposed to reactive oxygen species (ROS). This is further
supported by evaluation of the GC–MS VIP scores (Sup-
plemental Fig. 7), which are high for both uric acid and
allantoin itself, indicating these features contribute strongly
to the differentiation of both conditions. Allantoin is often
used as an oxidative marker (Yardim-Akaydin et al. 2006).
Oxidative stress is a frequently discussed topic in AD
research, since it may precede the appearance of patho-
logical hallmarks, e.g. senile plaques and neurofibrillary
tangles (Perry et al. 2002). Oxidative stress in AD is
probably the result of a disturbed redox balance due to
malfunctioning of the mitochondria (Zhao and Zhao 2013).
Both amyloid-b and tau can be found in the mitochondria
where they dysregulate the oxidative phosphorylation
system (complex IV and I, respectively) (Rhein et al.
2009), associated with an increased ROS production. This
could then indeed set the scene for the observed increase in
allantoin levels.
Upon expression of amyloid-b, tyrosine was upregu-
lated in both LC- and GC–MS analyses, indicating the
robustness of this result. Alterations of the tyrosine
pathway in CSF, serum and autopsy-confirmed brain tis-
sue of AD patients were also previously observed
(Kaddurah-Daouk et al. 2011; Trushina et al. 2013).
Tyrosine is an important precursor of the neurotransmitter
dopamine, and of the catecholamines norepinephrine and
epinephrine. When dopamine is formed, tyrosine is pro-
cessed by tyrosine hydroxylase (TH). A reduced activity
of TH (Trillo et al. 2013) and norepinephrine/epinephrine
(Kaddurah-Daouk et al. 2011) have been observed in AD
patients. The here observed upregulation of tyrosine
might therefore be due to a reduced activity of TH, but
this remains to be confirmed.
A decreased cystathionine concentration was observed
after the expression of amyloid-b in C. elegans. Polymor-
phisms in cystathionine beta synthase (CBS), catalyzing
the conversion of homocysteine to cystathionine, are well-
known risk factors for AD (Perluigi and Butterfield 2012).
These gene polymorphisms are known to decrease CBS
activity and cause a high concentration of homocysteine
and a low concentration of cystathionine (Bi et al. 2010), in
line with our observations in C. elegans.
Table 3 Features related to AD pathology from LC–MS analysis
(p value \0.01)
LC–MS differential features
m/z value RT p value* Z-factor Fold change Mode
180.065 1.3 0.0446 -2.63 1.36 RP-
Identified as tyrosine (C9H11NO3, [M–H]–)
173.1108 3.1 0.0017 -1.38 2.11 ANP?
131.1159 7 0.0017 -1.07 4.76 ANP?
169.0724 7 0.0017 -1.1 3.21 ANP?
230.1783 8.1 0.0017 -0.19 7.92 ANP?
384.1027 1.4 0.0037 -2.06 0.57 RP-
509.3433a 12.4 0.0037 -1.1 9.54 RP-
929.62740 11.6 0.005 -1.35 15.77 RP-
464.57130 11.6 0.005 -1.83 5.48 RP-
366.1274 12.7 0.005 -1.71 9.96 RP-
929.8786 3.8 0.005 -0.72 4.03 RP-
114.0901 0.8 0.0052 -1.37 2.91 RP?
448.2284 9.7 0.0052 -1.89 2.35 RP?
131.1167 0.8 0.0061 -1.36 3.56 RP?
362.2059 8.8 0.0061 -2.09 2.56 RP?
131.2164 0.8 0.0061 -1.62 2.72 RP?
485.1334 4.4 0.0061 -1.3 7.21 RP?
516.0773 3.7 0.0061 -1.77 3.87 RP?
131.0899 0.8 0.0068 -1.84 2.85 RP?
397.2089 8.5 0.0068 -2.05 3.35 RP?
173.1239 3 0.0084 -0.69 3.39 ANP?
449.1221 8 0.0096 -2.1 6.72 RP-
m/z value, retention time, p value (*adjusted according to the Ben-
jamini and Hochberg principle), Z-factor, fold change, separation-
detection mode and putative similarities with literature are provided.
For tyrosine, formula and adduct ion are also shown. Z-factor pro-
vides a useful tool for comparison and evaluation of the quality of the
assay (Zhang 1999). Adducts were combined and indicated with 0
a Confirmed in Lin et al. 2013. Accurate mass of tyrosine in Sup-
plemental Table 4
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The clear correlations of these identified, differential
metabolites with vertebrate AD pathology support the
robustness of the C. elegans model system.
3.4 Long-lived C. elegans exhibit opposite alterations
Because C. elegans is also a well-established model system
for aging research, there is added value in comparing
information for long-lived, healthy strains with the here
used AD strain. This is because the latter is hallmarked by
a decreased lifespan and impaired learning behavior due to
neurodegeneration (Dosanjh et al. 2010), therefore dis-
playing opposite phenotypes. Proteomic analysis (Depuydt
et al. 2014) of the long-lived daf-2 mutant revealed an
increase in tyrosine catabolism. This contrasts with the
higher levels of tyrosine observed in the AD model used
here. Similarly, a strong upregulation of CBS is observed
in the long-lived daf-2 mutant (Depuydt et al. 2014),
implying increased concentrations of cystathionine. This
again confirms the molecular basis for the opposite phe-
notypes. As more and more-omics data are becoming
available, such comparisons could in the future assist in
discriminating general, aging-related effects from more
AD-specific perturbations.
3.5 Prospects
Although our results are promising and some comparisons
with human AD pathology could be made, elaborate
comparison of studies is not straightforward. This has a
dual reason: for one, human studies rely on very distinct
sample types. Brain tissue, on one hand, can only be used
from post-mortem patients and often suffers from degra-
dation. CSF from patients, on the other hand, is an
achievable alternative, but implies a change towards indi-
rect results from a biofluid, rather than direct information
from the affected tissue. In addition, limited effort is made
for the complete determination of the metabolic fingerprint.
This is readily understood from the set of metabolic
markers discussed above, which do not (yet) display any
clear biological coherence or pathway logic. If we want to
accurately map the pathological process, complete identi-
fied metabolic fingerprints—which represent the compre-
hensive status of all extracted metabolites—should be
compared over time in profiling experiments. This strategy
will allow for the robust discovery of potential biomarker
candidates and grants an invaluable advantage to comple-
mentary compound screens. After administration of a cer-
tain lead compound, the fingerprint can indicate which
(sub)processes are altered. Currently, essential information
can easily be overlooked due to the partial identification of
the fingerprints. Such analyses should ideally be performed
preclinical, in a controlled model where metabolic finger-
prints can be identified more easily.
3.6 Concluding remarks
Our results show that C. elegans has the abilities to develop
into an amenable model for AD metabolomics experi-
ments. The here described set of metabolites provide a
blueprint for future completion of the AD fingerprint, as
such further refining our mechanistic insights into this
devastating disease. Metabolomic analyses, compound
screenings and biomarker discovery require an exceptional
high level of experimental control. Future experiments with
optimized double transgenic worms, expressing amyloid-b
and tau together, will therefore be invaluable to assist in the
advances of metabolomics with regards to AD progression.
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